SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to s ...

6 Of Goldman Sachs Top 2024 Stock Picks Also Pay Big Dividends Chris Hondros / Getty Images The Artificial Intelligence rally over the last year, led by the so-called “Magnificent 7,” has been fantastic if you owned those stocks. However, most of the S&P 500 is treading water and will not likely ever catch up to the hype-driven AI stocks soon.With the market trading at all-time highs, investors will likely be lured into a false sense of financial security. The reality is the United States could be set for ...

The board of directors of General Dynamics today declared a regular quarterly dividend of $1.42 per share on the company's common stock, payable May 10, 2024, to shareholders of record on April 12, 2024. This is the 27th consecutive annual dividend increase authorized by the General Dynamics board and represents a 7.6% increase over last year's dividend.10 mREITs With Impressive Yields »Amgen today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The ...

THOUSAND OAKS, Calif., March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024, to all stockholders of record as of the close of business on May 17, 2024. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This a ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this world's largest biotech drugmaker have returned -12.5% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has gained 1% over this period. Now the key question is: Where could the stock be headed in the near term?Wh ...

Amgen Inc. (NASDAQ:AMGN) TD Cowen 44th Annual Health Care Conference March 5, 2024 9:10 AM ET Company Participants Peter Griffith - Chief Financial Officer Paul Burton - Chief Medical Officer Conference Call Participants Yaron Werber - TD Cowen Yaron Werber All right. Well, welcome once again to the 44th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the Biotech team, and it's a great pleasure to moderate the fireside chat next with Amgen, first fireside chat for the day, so have very high ex ...

Amgen (AMGN) ended the recent trading session at $279.35, demonstrating a -0.35% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.12%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.41%.Prior to today's trading, shares of the world's largest biotech drugmaker had lost 13.26% over the past month. This has lagged the Medical sector's gain of 3.58% and the S&P 500's gain of 4.83% in that time.The upcoming ...

Much like Big Tech companies ride the AI hype, pharma stocks are counting on valuation boosts from big drug hits and FDA approvals. This anticipation, however, brings to light the importance of discerning which pharma stocks to sell, as not all will sustain their high-growth promises, potentially generating double-digit profits in the short term.This perspective often invites speculation that leads to overvaluation. Over the last three months, the SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) is up nearly 22% ...

Core Insights - Amgen has opened a new manufacturing facility in Central Ohio, named Amgen Ohio, which is the most advanced in its global operations network [1] - The facility spans nearly 300,000 square feet and will employ 400 full-time staff, contributing to a $40 million annual payroll [2] - Amgen Ohio is designed to meet high environmental sustainability standards, aligning with the company's goal of achieving carbon neutrality by 2027 [1][2] Company Overview - Amgen is a leading independent biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics [3] - The company utilizes advanced human genetics to address serious diseases and improve health outcomes [3] - Amgen has been recognized as one of the 30 companies in the Dow Jones Industrial Average and has received accolades for its workplace environment and climate leadership [4]

The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem likely to happen in the next decade.Of course, investing in just any biotech stock won't do. It's important to decide whether a company has the innovative capabilities to stay relevant and continuously deliver strong returns. Let's consider three biotech stocks that have wha ...